Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership
Fifty1 AI Labs (OTC: FITY) has successfully completed the REVIVE Phase III clinical trial for Long COVID treatment, marking a significant breakthrough in AI-driven drug repurposing. The trial, conducted in collaboration with prestigious institutions including Stanford and Duke University, enrolled over 600 participants globally and represents the largest Long COVID study to date.
The company aims to achieve a $50 million valuation while targeting the $320.6 billion functional medicine market. The trial's success is powered by Fifty1's proprietary Bayesian and Predictive Platform, developed through a $1 million R&D investment. The company plans to uplist to OTCQB by Q1 2026 and eventually to NASDAQ, with upcoming product launches and a virtual shareholder teleconference scheduled for July 28, 2025.
Fifty1 AI Labs (OTC: FITY) ha completato con successo la sperimentazione clinica di fase III REVIVE per il trattamento del Long COVID, segnando un importante progresso nel riutilizzo di farmaci guidato dall'intelligenza artificiale. Lo studio, realizzato in collaborazione con prestigiose istituzioni come Stanford e Duke University, ha coinvolto oltre 600 partecipanti a livello globale ed 猫 il pi霉 grande studio sul Long COVID finora condotto.
L'azienda punta a raggiungere una valutazione di 50 milioni di dollari mirando al mercato della medicina funzionale da 320,6 miliardi di dollari. Il successo della sperimentazione 猫 supportato dalla piattaforma proprietaria Bayesiana e Predittiva di Fifty1, sviluppata grazie a un investimento in R&S di 1 milione di dollari. La societ脿 prevede di passare all'OTCQB entro il primo trimestre del 2026 e successivamente al NASDAQ, con il lancio di nuovi prodotti e una teleconferenza virtuale per gli azionisti programmata per il 28 luglio 2025.
Fifty1 AI Labs (OTC: FITY) ha completado con 茅xito el ensayo cl铆nico de fase III REVIVE para el tratamiento de Long COVID, marcando un avance significativo en la reutilizaci贸n de f谩rmacos impulsada por inteligencia artificial. El estudio, realizado en colaboraci贸n con prestigiosas instituciones como Stanford y la Universidad de Duke, incluy贸 a m谩s de 600 participantes a nivel mundial y representa el mayor estudio sobre Long COVID hasta la fecha.
La empresa aspira a alcanzar una valoraci贸n de 50 millones de d贸lares mientras apunta al mercado de la medicina funcional de 320.6 mil millones de d贸lares. El 茅xito del ensayo se basa en la plataforma bayesiana y predictiva propietaria de Fifty1, desarrollada mediante una inversi贸n en I+D de 1 mill贸n de d贸lares. La compa帽铆a planea ascender al OTCQB para el primer trimestre de 2026 y eventualmente al NASDAQ, con pr贸ximos lanzamientos de productos y una teleconferencia virtual para accionistas programada para el 28 de julio de 2025.
Fifty1 AI Labs (OTC: FITY)電� 鞛リ赴 旖旊雮� 旃橂毳� 鞙勴暅 REVIVE 3靸� 鞛勳儊鞁滍棙鞚� 靹标车鞝侅溂搿� 鞕勲頃橂┌ AI 旮半皹 鞎诫 鞛櫆鞖� 攵勳暭鞐愳劀 欷戩殧頃� 霃岉寣甑ゼ 毵堧牗頄堨姷雼堧嫟. 鞀ろ儬韽摐鞕� 霌�韥� 雽�頃� 霌� 氇呺 旮瓣磤霌り臣 順戨牓頃橃棳 鞝� 靹戈硠 600氇� 鞚挫儊鞚� 彀戈皜鞛�毳� 雽�靸侅溂搿� 歆勴枆霅� 鞚措矆 鞛勳儊鞁滍棙鞚� 歆�旮堦箤歆� 臧�鞛� 韥� 鞛リ赴 旖旊雮� 鞐瓣惮鞛呺媹雼�.
须岇偓电� 5觳滊 雼煬 韽夑皜鞎� 雼劚鞚� 氇╉憸搿� 頃橂┌ 3,206鞏� 雼煬 攴滊鞚� 旮半姤靹� 鞚橅暀 鞁滌灔鞚� 瓴儱頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞛勳儊 靹标车鞚� 100毵� 雼煬鞚� 鞐瓣惮臧滊皽 韴瀽搿� 臧滊皽霅� Fifty1鞚� 霃呾瀽鞝侅澑 氩犾澊歆�鞎� 氚� 鞓堨浮 頂岆灚韽检棎 旮半皹頃╇媹雼�. 须岇偓电� 2026雲� 1攵勱赴旯岇 OTCQB搿� 靸侅灔 鞚挫爠鞚� 瓿勴殟頃橁碃 鞛堨溂氅�, 鞚错泟 NASDAQ 靸侅灔霃� 於旍 欷戩瀰雼堧嫟. 鞁犾牅頀� 於滌嫓鞕� 2025雲� 7鞗� 28鞚� 鞓堨爼霅� 臧�靸� 欤检＜ 鞝勴檾須岇潣霃� 欷�牍勴晿瓿� 鞛堨姷雼堧嫟.
Fifty1 AI Labs (OTC : FITY) a r茅ussi 脿 terminer l'essai clinique de phase III REVIVE pour le traitement du Long COVID, marquant une avanc茅e majeure dans le repositionnement de m茅dicaments assist茅 par intelligence artificielle. L'essai, r茅alis茅 en collaboration avec des institutions prestigieuses telles que Stanford et l'Universit茅 Duke, a recrut茅 plus de 600 participants 脿 l'茅chelle mondiale et constitue la plus grande 茅tude sur le Long COVID 脿 ce jour.
L'entreprise vise une valorisation de 50 millions de dollars tout en ciblant le march茅 de la m茅decine fonctionnelle de 320,6 milliards de dollars. Le succ猫s de l'essai repose sur la plateforme bay茅sienne et pr茅dictive propri茅taire de Fifty1, d茅velopp茅e gr芒ce 脿 un investissement en R&D de 1 million de dollars. La soci茅t茅 pr茅voit de passer 脿 l'OTCQB d'ici le premier trimestre 2026, puis 茅ventuellement au NASDAQ, avec des lancements de produits 脿 venir et une t茅l茅conf茅rence virtuelle pour les actionnaires pr茅vue le 28 juillet 2025.
Fifty1 AI Labs (OTC: FITY) hat die REVIVE Phase-III-Studie zur Behandlung von Long COVID erfolgreich abgeschlossen und damit einen bedeutenden Durchbruch im KI-gesteuerten Drug Repurposing erzielt. Die Studie wurde in Zusammenarbeit mit renommierten Institutionen wie Stanford und der Duke University durchgef眉hrt, umfasste 眉ber 600 Teilnehmer weltweit und ist die bislang gr枚脽te Long-COVID-Studie.
Das Unternehmen strebt eine Bewertung von 50 Millionen US-Dollar an und fokussiert sich auf den 320,6 Milliarden US-Dollar gro脽en Markt der funktionellen Medizin. Der Erfolg der Studie basiert auf Fifty1s propriet盲rer Bayesscher und pr盲diktiver Plattform, die durch eine F&E-Investition von 1 Million US-Dollar entwickelt wurde. Das Unternehmen plant, bis zum ersten Quartal 2026 an das OTCQB zu wechseln und sp盲ter an die NASDAQ zu gehen, mit bevorstehenden Produkteinf眉hrungen und einer virtuellen Aktion盲rstelefonkonferenz am 28. Juli 2025.
- Successful completion of Phase III REVIVE trial - the largest Long COVID study to date with 600+ participants
- Strategic positioning in $320.6B functional medicine market with 13.8% CAGR
- $1M R&D investment in proprietary AI platform showing successful results
- Clear uplisting strategy to OTCQB (Q1 2026) and NASDAQ
- Planned strategic acquisitions in $5-10M range to enhance R&D capabilities
- Currently trading on OTC markets, indicating higher risk profile
- Significant capital requirements needed for planned acquisitions and R&D expansion
- Trial results still under peer review, pending final validation
- Website and product offerings not yet launched, indicating early-stage development
Pioneering a New Era in Healthcare: AI-Driven Innovation Unlocks Transformative Therapies and Drives Path to
SEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University (Canada), and global partners, proudly announces the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967). This historic Phase III, multicenter, adaptive, randomized, double-blind, placebo-controlled trial, the largest and most rigorous Long COVID study to date, marks a pivotal milestone in addressing a global health crisis affecting approximately 400 million people and
A Landmark Achievement in Long COVID Research and Functional Medicine
The REVIVE Trial is the first adaptive platform trial to demonstrate a clear treatment benefit for Long COVID, leveraging repurposed medicines to address this debilitating condition. This breakthrough aligns seamlessly with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting high-growth areas like preventative healthcare within the
Unprecedented Scale, Speed, and Scientific Excellence
As the largest completed Long COVID trial, REVIVE enrolled over 600 participants across multiple global sites, achieving the fastest recruitment of any study of its kind. This feat was made possible through Fifty1 AI Labs' operational excellence and strategic partnerships with world-class institutions, guided by the company's elite management team. The trial's rigorous execution and robust data collection underscore Fifty 1 Labs, Inc.'s commitment to scientific excellence and operational efficiency, key pillars of its Game Plan to enhance shareholder visibility and liquidity through uplisting and strategic growth initiatives.
Powered by Fifty1 AI Labs' Cutting-Edge AI Platform
The REVIVE Trial's success is driven by Fifty1 AI Labs' proprietary Bayesian and Predictive Platform, a cornerstone of Fifty 1 Labs, Inc.'s
Catalyzing Transformative Therapies and Intellectual Property Growth
The REVIVE Trial's findings, currently under peer review at a leading medical journal, establish a foundation for polypharmacy-based treatment regimens using repurposed drugs delivered through innovative systems such as transdermal and sublingual formulations. These advancements unlock significant opportunities for intellectual property (IP) development, enabling Fifty 1 Labs, Inc. to build a robust portfolio of proprietary therapeutic platforms. By securing IP rights and developing commercially viable products, the company is poised to capture a substantial share of the Long COVID treatment market, projected to generate billions in annual revenue. This strategic focus on IP and commercialization aligns with Fifty 1 Labs, Inc.'s Game Plan to pursue strategic acquisitions in the
"The REVIVE Trial is a testament to our vision of transforming healthcare through AI-driven innovation," said Dr. Paul Arora, CEO of Fifty 1 Labs, Inc. "By leveraging Fifty1 AI Labs' cutting-edge platform and our world-class partnerships, we are delivering hope to millions affected by Long COVID while creating a scalable model for future breakthroughs in functional medicine. Our Game Plan positions FITY to lead the biotech industry, driving exponential growth and exceptional returns for our shareholders."
Strategic Outlook: A Roadmap for Global Leadership
The REVIVE Trial's success is a critical step in Fifty 1 Labs, Inc.'s Game Plan to achieve a
For More Information
To learn more about Fifty 1 Labs, Inc., Fifty1 AI Labs, LLC, or the REVIVE Trial, visit or contact . Join us for the Virtual Shareholder Teleconference on X (@Fifty1Labs) on July 28, 2025, at 4:00 PM EST to hear directly from our leadership team.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. (OTC: FITY), a Nevada-based biotech pioneer, is transforming healthcare through AI-driven drug repurposing and functional medicine. Through its subsidiaries, the company delivers innovative, data-driven solutions for preventative healthcare and performance nutrition. Committed to revolutionizing personalized medicine, Fifty 1 Labs is poised to lead the biotech and wellness industries, creating lasting value for shareholders through cutting-edge innovation and strategic growth.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, and expectations regarding future events or performance. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
Email:
Phone: (877) 505-5006
Website:
FAQ
What are the key findings of Fifty1 AI Labs' (FITY) REVIVE clinical trial for Long COVID?
What is Fifty1 AI Labs' (FITY) target valuation and market opportunity?
When will Fifty1 AI Labs (FITY) uplist to major exchanges?
What is the upcoming catalyst timeline for Fifty1 AI Labs (FITY) stock?
How much has Fifty1 AI Labs (FITY) invested in R&D?
